biostudies-literatureUnknown111(4)Korenblik RDRAGON trials<h4>Background</h4>The purpose of this study was to compare 3-year overall survival after simultaneous portal (PVE) and hepatic vein (HVE) embolization versus PVE alone in patients undergoing liver resection for primary and secondary cancers of the liver.<h4>Methods</h4>In this multicentre retrospective study, all DRAGON 0 centres provided 3-year follow-up data for all patients who had PVE/HVE or PVE, and were included in DRAGON 0 between 2016 and 2019. Kaplan-Meier analysis was undertaken to assess 3-year overall and recurrence/progression-free survival. Factors affecting survival were evaluated using univariable and multivariable Cox regression analyses.<h4>Results</h4>In total, 199 patients were included from 7 centres, of whom 39 underwent PVE/HVE and 160 PVE alone. Groups differed in median age (P = 0.008). As reported previously, PVE/HVE resulted in a significantly higher resection rate than PVE alone (92 versus 68%; P = 0.007). Three-year overall survival was significantly higher in the PVE/HVE group (median survival not reached after 36 months versus 20 months after PVE; P = 0.004). Univariable and multivariable analyses identified PVE/HVE as an independent predictor of survival (univariable HR 0.46, 95% c.i. 0.27 to 0.76; P = 0.003).<h4>Conclusion</h4>Overall survival after PVE/HVE is substantially longer than that after PVE alone in patients with primary and secondary liver tumours.The British journal of surgeryznae087https://www.ebi.ac.uk/biostudies/studies/S-EPMC11044894biostudies-literatureLiver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohort.PMC11044894Williams MKorenblik RBreitenstein SStavrou GSchadde ECrawford MTeichgraber UE CAMartin ESMadoff DCPeddu PImani FDamink SWMOSerenari MLapisatepun WJames SMartel GSparrelid EBemelmans MHABechstein WOKalil JAFouraschen SNavines Lopez JSoonawalla ZFont JCLopez-Ben SSandstrom PBent CChan BDetry OBruners PLucidi VFisher OUdupa VHoffmann MSmits JRatti FSpuentrup EVogl TSutcliffe RAldrighetti LDeprez FLeclercq WMoragues JSSallemi CSnitzbauer AWhite SYu DSarria LDRAGON trials collaborativede Boer MTFundora YFretland AAGuitart Gimenez JGerard LPrimrose JI Robert MCCarling UWinkens BMacdonald AQu XInmutto NKalil JDe Cobelli FRaptis DAMeijerink MOlde Damink SWMValenti DAvan Dam RMOlij BDelle MBorobia FGArslan BKleeff JZijlstra IJAJErdmann JICha CDili ACroagh DVass DHess GHilal MAGruenberger TModi SDavis RRinkes IHMBSmits MLJSerrablo AKingham PSchnitzbauer AAGuiliante FWang XRonellenfitsch USettmacher UBreen DGrunhagen DDe Wispelaere JFHagendoorn JGrote JBokkers RPHGrochola LFBinkert CIezzi RGobardhan PDiaz-Nieto RJovine EHeil JMetrakos PRogan CTancredi IBarbier LNeumann UPDewulf MGelabert AKollmar OPennetta FRyan SBaclija IPappas SGBinkert CAChoi Jvan Baardewijk LFernando RSalik Avan der Leij Cde Boo DMenon KRidouani FTasse JCBjornsson BCappelli AMehrzad HHerrero ELindsay RNguyen JGomez FHeise DDewulf MJLMontanari NWohlgemuth WfalseLiver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohort.<h4>Background</h4>The purpose of this study was to compare 3-year overall survival after simultaneous portal (PVE) and hepatic vein (HVE) embolization versus PVE alone in patients undergoing liver resection for primary and secondary cancers of the liver.<h4>Methods</h4>In this multicentre retrospective study, all DRAGON 0 centres provided 3-year follow-up data for all patients who had PVE/HVE or PVE, and were included in DRAGON 0 between 2016 and 2019. Kaplan-Meier analysis was undertaken to assess 3-year overall and recurrence/progression-free survival. Factors affecting survival were evaluated using univariable and multivariable Cox regression analyses.<h4>Results</h4>In total, 199 patients were included from 7 centres, of whom 39 underwent PVE/HVE and 160 PVE alone. Groups differed in median age (P = 0.008). As reported previously, PVE/HVE resulted in a significantly higher resection rate than PVE alone (92 versus 68%; P = 0.007). Three-year overall survival was significantly higher in the PVE/HVE group (median survival not reached after 36 months versus 20 months after PVE; P = 0.004). Univariable and multivariable analyses identified PVE/HVE as an independent predictor of survival (univariable HR 0.46, 95% c.i. 0.27 to 0.76; P = 0.003).<h4>Conclusion</h4>Overall survival after PVE/HVE is substantially longer than that after PVE alone in patients with primary and secondary liver tumours.2024-01-01T00:00:00Z2024 Apr2026-06-03T03:55:34.075Z2026-04-24T03:09:34.973ZS-EPMC110448943866246210.1093/bjs/znae087